Home PageAll MoleculesMesothelin
Mesothelin
Mesothelin
Mesothelin Overview
Molecule Name
Mesothelin
Synonyms
MSLN,Mesothelin,MPF
Drug Development Progress
Drugs in Clinical Trials59
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Pre-pro-megakaryocyte-potentiating factor，Mesothelin，MSLN，CAK1 Antigen，MPF，Soluble MPF Mesothelin Related Protein，Megakaryocyte Potentiating Factor，SMRP，CAK1
Background
Mesothelin (MSLN) is also known as CAK1 antigen, Pre-pro-megakaryocyte-potentiating factor, which belongs to the mesothelin family. Mesothelin / MSLN can be proteolytically cleaved into the following two chains by a furin-like convertase: Megakaryocyte-potentiating factor (MPF) and the cleaved form of mesothelin. Both MPF and the cleaved form of mesothelin are N-glycosylated. Mesothelin / MSLN can interacts with MUC16. The membrane-anchored forms of MSLN may play a role in cellular adhesion. MPF potentiates megakaryocyte colony formation in vitro.
Mesothelin Product List
No Data
You Have Viewed 0 Of 0 Results
- 1
No Data
No Data
Can’t find what you need?
Submit your requirements and our technical
team will help.
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| RC-88 | RC-88 | Phase 2 Clinical | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours | Details | |
| iCasp9M28z | iCasp9M28z | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Breast Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasm Metastasis; Pleural Diseases | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 2 Clinical | Bayer AG, Morphosys Ag | Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours | Details |
| Gavocabtagene autoleucel | TC-210 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Mesothelioma; Ovarian Neoplasms | Details |
| LMB-100 | LMB-100; RG-7787; RO-6927005 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Adenocarcinoma of Lung; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Lung Neoplasms; Mesothelioma; Neoplasms; Neoplasms, Mesothelial; Pancreatic Neoplasms; Pleural Effusion, Malignant | Details |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| EB-DNK101 | EB-DNK101 | Phase 2 Clinical | Beijing Biotech | Carcinoma, Pancreatic Ductal | Details |
| EB-NK-MM (MSLN/MUC16) | EB-NK-MM | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Details |
| EB-NK-MF (MSLN/FRalpha) | EB-NK-MF | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Glioblastoma; Glioma; Peritoneal Neoplasms | Details |
| EB-DuoNK-MSLN/HER2 cell therapy (Beijing Biotech) | Phase 2 Clinical | Beijing Biotech | Carcinoma, Non-Small-Cell Lung | Details | |
| MSLN CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Solid tumours | Details | |
| A2B-543 | A2B543 | Phase 2 Clinical | A2 Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Solid tumours | Details |
| Mesothelin targeting CAR-T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Pancreatic Neoplasms | Details | |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| TCR-like CAR-T Cell Therapy(Zhongda Hospital Southeast University) | Phase 2 Clinical | Zhongda Hospital Southeast University | Ovarian Neoplasms | Details | |
| CD40 ligand expressing MSLN-CAR T cells | Phase 2 Clinical | Pla General Hospital | Solid tumours | Details | |
| A2B-694 | A2B-694; A2B694 | Phase 2 Clinical | A2 Biotherapeutics Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Solid tumours | Details |
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| CART-meso | CART-meso | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Adenocarcinoma of Lung; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Fallopian Tube Neoplasms; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms | Details |
| anti-MESO CAR-T cells (Zhejiang University) | UCLM802; UCLM-802 | Phase 1 Clinical | Hrain Biotechnology Co Ltd, Zhejiang University | Ovarian Neoplasms; Solid tumours | Details |
| Anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Phase 1 Clinical | Bayer AG | Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms | Details |
| huMesoCART | MSLN-12; MSLN-18; SS-1; MSLN-23; MSLN-11; MSLN-14; MSLN-16; MSLN-21; MSLN-5 | Phase 1 Clinical | University Of Pennsylvania | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms | Details |
| PSMA/NKG2DL/FAP-targeted Hi-TCR-T cells | Phase 1 Clinical | Shenzhen Misheng Biotechnology Co Ltd | Prostatic Neoplasms; Solid tumours | Details | |
| GC-503 | GC-503 | Phase 1 Clinical | Gracell Biotechnologies Inc | Solid tumours | Details |
| iCasp9M28z T cells | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Breast Neoplasms; Lung Neoplasms; Mesothelioma | Details | |
| anti-mesothelin CAR T-cell therapy (Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Solid tumours | Details | |
| HPN-536 | HPN-536 | Phase 1 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| AB-1015 | AB-1015 | Phase 1 Clinical | Arsenal Biosciences Inc | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms | Details |
| SynKIR-110 | SynKIR™-110; SynKIR-meso | Phase 1 Clinical | Verismo Therapeutics Inc | Cholangiocarcinoma; Mesothelioma; Ovarian Neoplasms | Details |
| KT-032 | KT-032 | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| NI-1801 | NI-1801 | Phase 1 Clinical | Light Chain Bioscience Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Solid tumours; Triple Negative Breast Neoplasms | Details |
| UCLM-805 | UCLM-805; UCLM805 | Phase 1 Clinical | UTC Therapeutics Inc | Solid tumours | Details |
| FC-004 | FC004; FC-004 | Phase 1 Clinical | Cancer Center Of Sun Yat Sen University | Ovarian Neoplasms | Details |
| MSLN-CAR T cells(Yihao Biotech) | SHYH006; SHYH-006 | Phase 1 Clinical | Shanghai Yihao Biotechnology Co Ltd | Ovarian Neoplasms | Details |
| Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells therapy(NIH) | TNhYP218; TNhYP217; TNhYP-218; TNhYP-217 | Phase 1 Clinical | National Cancer Institute | Colonic Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms; Thymus Neoplasms | Details |
| Mesothelin x CD3 Bispecific Antibody(Integral Molecular) | CT-95; LNK101; LNK-101 | Phase 1 Clinical | Integral Molecular Inc | Carcinoma, Ovarian Epithelial; Cholangiocarcinoma; Colorectal Neoplasms; Mesothelioma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| BZT-2312 | BZT-2312 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
| JNJ-79032421 | JNJ-79032421; JNJ-2421 | Phase 1 Clinical | Janssen Research & Development Llc | Solid tumours | Details |
| YL-215 | YL215; YL-215 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| GPC3/Mesothelin-CAR-γδT Cells therapy(Second Affiliated Hospital Of Guangzhou Medical University) | Phase 1 Clinical | Second Affiliated Hospital Of Guangzhou Medical University | Liver Neoplasms; Lung Neoplasms; Mesothelioma; Pancreatic Neoplasms; Solid tumours | Details | |
| OPB-101 | OPB-101 | Phase 1 Clinical | Outpace Bio Inc | Ovarian Diseases; Ovarian Neoplasms | Details |
| AMG 305 | AMG 305; AMG-305 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| Mesothelin-CAR-T Cells (Fapon Biopharma) | Phase 1 Clinical | Guangdong Fapon Biopharma Inc | Pancreatic Neoplasms | Details | |
| UCMYM-802 | UCMYM802; UCMYM-802 | Phase 1 Clinical | UTC Therapeutics Inc | Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Solid tumours | Details |
| HBM-9033 | HBM9033; SGN-MesoC2; HBM-9033; PF-08052666 | Phase 1 Clinical | Nona Biosciences | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| LD-013 | LD013; LD-013 | Phase 1 Clinical | Nanjing Blue Shield Biotech Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| Ori-C-613 | Ori-C-613; OriC-613; Ori-C613 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| RD-138 | RD-138 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Multiple Myeloma | Details |
| RD-133 | RD133 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Neoplasms; Solid tumours | Details |
| PM-3006 | PM-3006 | Phase 1 Clinical | Details | ||
| Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) | ALF-101 | Phase 1 Clinical | Guojianchengnuo Biotechnology (Beijing) Co Ltd | Carcinoma, Ovarian Epithelial | Details |
| Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| ATA-2271 | ATA-2271 | Phase 1 Clinical | Atara Biotherapeutics Inc, Bayer AG, Memorial Sloan Kettering Cancer Center | Adenocarcinoma; Breast Neoplasms; Diabetes Mellitus; Esophageal adenocarcinoma; Esophageal Neoplasms; Mesothelioma; Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | Details |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | BZDS1901; BZDS-1901; BZD1901 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Mesothelioma; Ovarian Neoplasms; Solid tumours | Details |
| KD-021 | KD-021 | Phase 1 Clinical | Nanjing Kaidi Medical Technology Co Ltd | Neoplasms | Details |
| anti-mesothelin CAR T-cell therapy (Shenzhen BinDeBio) | Clinical | Shenzhen Bindebio Ltd | Pancreatic Neoplasms | Details | |
| Universal Chimeric Antigen Receptor T-Cell Immunotherapy(Calmhome Cell and Gene Engineering Institute) | CHT-102; CHT102 | Clinical | Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd, Tianjin Medical University Cancer Institute And Hospital | Pancreatic Neoplasms; Solid tumours | Details |
| Anti-mesothelin CAR T cell therapy (UTC Therapeutics Inc) | Clinical | UTC Therapeutics Inc | Solid tumours | Details | |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details |
B***a2023-07-11This is one of the only conjugated mesothelin proteins available on the market! It has great specificity for flow cytometry staining, this has been a game changer for us to measure human mesothelin present in our samples with an easy and quick one-step staining method. This is a great quality product and we will be ordering so many more in the future!